Gemcitabine exhibits cell phase specificity and acts primarily on the S phase. It also inhibits cell progression through the G1/S-phase boundary. Gemcitabine is metabolized intracellularly to diflurodeoxycytidine monophosphate (dFdCMP) that is then converted into diphosphate (dFdCDP) and triphosphate (dFdCTP) forms, the metabolites that give the drug its activity. The diphosphate inhibits ribonucleotide reductase. The triphosphate competes with deoxycytidine triphosphate (dTCP; the “normal” nucleotide) for incorporation into DNA strands.
Gemfibrozil may be useful to reduce serum triglycerides in those dogs or cats with hypertriglyceridemia and when diet modifications alone have been unsuccessful. One reference (Elliott 2005) suggests not adding drug therapy to treat hypertriglyceridemia unless the serum triglyceride concentration exceeds 500 mg/dL with associated clinical signs.
劑量數字暫停提供：VetPro 的劑量改依 DRUGAPI 藥物資料庫對外的內容，DRUGAPI 目前不提供可直接計算的劑量。下方列出 DRUGAPI 的審查結論與劑量審查引用的來源；計算機可手動輸入劑量換算。
確認精確產品與活性部分等價量 確認物種、腫瘤、分期、既往治療與合併療法 由獸醫腫瘤專科團隊設定與覆核個案方案 依個案建立血液學、器官功能與毒性監測 依危險藥物規範處理、清潔與廢棄
依出現頻率分組；嚴重副作用獨立列出，臨床上需立即辨識。